ImmunoGen Inc (IMGN)
US45253H1014 - Common Stock
Taking everything into account, IMGN scores 3 out of 10 in our fundamental rating. IMGN was compared to 588 industry peers in the Biotechnology industry. IMGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IMGN had negative earnings in the past year.
IMGN had a negative operating cash flow in the past year.
In the past 5 years IMGN always reported negative net income.
IMGN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IMGN (-8.94%) is better than 89.06% of its industry peers.
With an excellent Return On Equity value of -13.09%, IMGN belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.94% | ||
| ROE | -13.09% | ||
| ROIC | N/A |
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMGN has a better Gross Margin (98.61%) than 98.32% of its industry peers.
The Profit Margin and Operating Margin are not available for IMGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMGN has been increased compared to 1 year ago.
The number of shares outstanding for IMGN has been increased compared to 5 years ago.
Compared to 1 year ago, IMGN has a worse debt to assets ratio.
2.2 Solvency
IMGN has an Altman-Z score of 18.14. This indicates that IMGN is financially healthy and has little risk of bankruptcy at the moment.
IMGN's Altman-Z score of 18.14 is amongst the best of the industry. IMGN outperforms 90.91% of its industry peers.
IMGN has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
IMGN has a Debt to Equity ratio of 0.16. This is in the lower half of the industry: IMGN underperforms 68.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 18.14 |
ROIC/WACCN/A
WACC11.02%
2.3 Liquidity
A Current Ratio of 5.69 indicates that IMGN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.69, IMGN is in line with its industry, outperforming 56.57% of the companies in the same industry.
IMGN has a Quick Ratio of 5.65. This indicates that IMGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.65, IMGN is in line with its industry, outperforming 56.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.69 | ||
| Quick Ratio | 5.65 |
3. Growth
3.1 Past
IMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.20%, which is quite impressive.
Looking at the last year, IMGN shows a very strong growth in Revenue. The Revenue has grown by 200.63%.
The Revenue has been decreasing by -1.17% on average over the past years.
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q132.26%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Revenue growth Q2Q636.36%
3.2 Future
The Earnings Per Share is expected to grow by 32.99% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 69.78% on average over the next years. This is a very strong growth
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IMGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 81.49 indicates a quite expensive valuation of IMGN.
Based on the Price/Forward Earnings ratio, IMGN is valued cheaper than 93.94% of the companies in the same industry.
IMGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.49.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 81.49 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IMGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as IMGN's earnings are expected to grow with 44.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.06%
EPS Next 3Y44.14%
5. Dividend
5.1 Amount
IMGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ImmunoGen Inc
NASDAQ:IMGN (2/9/2024, 7:00:02 PM)
After market: 31.24 +0.01 (+0.03%)31.23
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.72B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 81.49 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.94% | ||
| ROE | -13.09% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.61% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.69 | ||
| Quick Ratio | 5.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y108.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y